Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 10/20 | 0.66 |
| ▸ | MMP1 | P03956 | 3/20 | 0.66 |
| ▸ | MMP3 | P08254 | 2/20 | 0.66 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.66 |
| ▸ | MMP2 | P08253 | 2/20 | 0.65 |
| ▸ | MMP12 | P39900 | 2/20 | 0.65 |
| ▸ | MMP13 | P45452 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504735 | 0.92 | ADAM17 (0.68) | ADAM17MMP1MMP3ADAM10MMP2 | |
| SCHEMBL1503661 | 0.89 | ADAM17 (0.64) | ADAM17MMP1ADAM10MMP2MMP12 | |
| SCHEMBL1504897 | 0.89 | ADAM17 (0.65) | ADAM17MMP1ADAM10MMP2MMP12 | |
| SCHEMBL1504791 | 0.87 | ADAM17 (0.66) | ADAM17MMP1MMP3ADAM10MMP2 | |
| SCHEMBL1504967 | 0.84 | ADAM17 (0.65) | ADAM17MMP1MMP3ADAM10MMP2 | |
| SCHEMBL1504779 | 0.84 | ADAM17 (0.61) | ADAM17MMP1MMP3ADAM10 | |
| SCHEMBL10276027 | 0.82 | ADAM17 (0.88) | ADAM17MMP1MMP3ADAM10MMP2 | |
| SCHEMBL1504725 | 0.82 | ADAM17 (0.88) | ADAM17MMP1MMP3ADAM10MMP2 | |
| SCHEMBL6598965 | 0.81 | ADAM17 (0.63) | ADAM17MMP1MMP3ADAM10MMP2 | |
| SCHEMBL1504974 | 0.81 | ADAM17 (0.60) | ADAM17MMP1MMP3ADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011033009-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |